cancer

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.

The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be designed to be "zero carbon" from its first day of operation in 2029.

Changing lifestyles and smoking are likely to kill 1 billion people this century, most of them in Asia, but a new scientific initiative aims to find cures.

The operator of cancer treatment centres avoids the fate of two other Chinese listing candidates which were forced to re-price or pull their US IPOs, but the stock still slumps 13.6% on the first day of trading.

Concord Medical Services aims to raise up to $138 million from an IPO and is expected to start trading on the NYSE late next week.